Bortezomib inhibits maturation and function of osteoclasts from pbmcs of patients with multiple myeloma by downregulating traf6.
September 11th, 2008 by 
admin | Related Articles |
Bortezomib inhibits maturement and duty of osteoclasts from PBMCs of patients with binary myeloma by downregulating TRAF6.
Leuk Res. 2008 Sep 6;
Authors: Hongming H, Jian H
Multiple myeloma (MM) is related with accumulated activation of osteoclasts, feat enhanced pearl humiliation and manufacture of lytic pearl lesions. In this study, we observed the restrictive gist of bortezomib on osteoclasts maturement and duty from marginal murder mononucleate cells (PBMCs) of MM patients, in an endeavor to explain the upstream molecular execution of bortezomib on osteoclastogenesis. Osteoclast precursors from PBMCs of octad MM patients were cultured in the proximity of organ activator of NF-kappaB ligand (RANKL) and macrophage-colony exciting bourgeois (M-CSF). Administration of 2.5 and 5nM bortezomib resulted in the change of osteoclast secernment by inferior manufacture of osteoclasts and the attenuated state take of TRAP. Osteoclast resorption power also decreased, suggesting that bortezomib was healthy to conquer the duty of osteoclasts. The results of Western-blot and RT-PCR assays advisable that bortezomib smothered osteoclasts by detractive TRAF6 creation at both accelerator and RNA levels. In conclusion, bortezomib acts on osteoclastgenesis at baritone concentrations by meddling with TRAF6 production, which strength establish to be a possibleness strategy for the communication of myeloma pearl disease.
PMID: 18778854 [PubMed - as supplied by publisher]
(Source: Leukemia Research)
Posted in Cancer | 